European Journal of Dermatology

, Volume 25, Issue 5, pp 392–403 | Cite as

Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma

  • Alfonso Berrocal
  • Enrique Espinosa
  • Severiano Marín
  • Josep Malvehy
  • David Moreno
  • Maria Dolores Lozano
  • Salvador Martin-Algarra
  • Jose Antonio Lopez
  • Carlos Conill
  • Jose Luis Rodriguez-Peralto


Advanced melanoma is a relatively uncommon condition whose therapeutic management has undergone major changes over the past four years. The present article aims to establish recommendations for the management of these patients based on the best available evidence reached by consensus of a group of professionals familiar in the treatment of these patients. These professionals, belonging to Spanish Multidisciplinary Melanoma Group, reviewed the diagnostic process and the incorporation of newtechniques of molecular diagnosis of advanced disease; treatment and monitoring of stage III both as adjuvant locoregional treatments have been addressed, as well as new therapies for stage IV.We have reviewed the palliative treatment alternatives for disseminated disease, such as surgery, radiotherapy or non-cytotoxic systemic treatments. Finally, we have also reviewed the most relevant toxicities of new drugs and their management in clinical practice.

Key words

advanced melanoma diagnosis therapeutic management 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Loblaw DA, Prestrud AA, Somerfield MR, et al. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 2012; 30: 3136. 40.PubMedCrossRefGoogle Scholar
  2. 2.
    Somerfield MR, Einhaus K, Hagerty KL, et al. American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol 2008; 26: 4022–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 2012; 167: 1124–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Avilés JA, Lázaro P, Lecona M. [Epidemiology and survival of cutaneous melanoma in Spain: a report of 552 cases (1994-2003)]. Rev Clínica Esp 2006; 206: 319–25.CrossRefGoogle Scholar
  5. 5.
    Salerni G, Carrera C, Lovatto L, et al. Benefits of total body photography and digital dermatoscopy (“two-step method of digital follow-up”) in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol 2012; 67: e17–27.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Salerni G, Lovatto L, Carrera C, Puig S, Malvehy J. Melanomas detected in a follow-up program compared with melanomas referred to a melanoma unit. Arch Dermatol 2011; 147: 549–55.PubMedCrossRefGoogle Scholar
  7. 7.
    Spillane AJ, Haydu LE, Lee NC, et al. Evaluation of incomplete sentinel node biopsy procedures and sentinel node positivity rates as surgical quality-assurance parameters in melanoma patients. Ann Surg Oncol 2012; 19: 3919–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol 2011; 5: 124–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Silva E. Adjunct primer for the use of national comprehensive cancer network guidelines for the surgical management of cutaneous malignant melanoma patients. World J Surg Oncol 2012; 10: 54.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011; 65: 1032–47.PubMedCrossRefGoogle Scholar
  11. 11.
    Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg Chic Ill 1960 1991; 126: 438–41.Google Scholar
  12. 12.
    Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318: 1159–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998; 14: 272–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Ringborg U, Andersson R, Eldh J, et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996; 77: 1809–14.PubMedCrossRefGoogle Scholar
  15. 15.
    Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89: 1495–501.PubMedCrossRefGoogle Scholar
  16. 16.
    Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003; 97: 1941–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7: 87–97.PubMedCrossRefGoogle Scholar
  18. 18.
    Lens MB, Nathan P, Bataille V. Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials. Arch Surg Chic Ill 1960 2007; 142: 885–91, discussion 891-893.Google Scholar
  19. 19.
    Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996; 3: 446–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262–7, discussion 267-269.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 1998; 5: 322–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 2006; 13: 809–16.PubMedCrossRefGoogle Scholar
  23. 23.
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307. 17.PubMedCrossRefGoogle Scholar
  24. 24.
    McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004; 86: 212–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Kingham TP, Panageas KS, Ariyan CE, Busam KJ, Brady MS, Coit DG. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol 2010; 17: 514–20.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg Chic Ill 1960 1989; 124: 1051–5.Google Scholar
  27. 27.
    Sabel MS, Griffith KA, Arora A, et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery 2007; 141: 728–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010; 17: 3324–9.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Nathansohn N, Schachter J, Gutman H. Patterns of recurrence in patients with melanoma after radical lymph node dissection. Arch Surg Chic Ill 1960 2005; 140: 1172–7.Google Scholar
  30. 30.
    Coit DG, Andtbacka R, Anker CJ, et al. Melanoma. J Natl Compr Cancer Netw JNCCN 2012; 10: 366–400.PubMedGoogle Scholar
  31. 31.
    Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010; 163: 238–56.PubMedCrossRefGoogle Scholar
  32. 32.
    Espinosa E, Berrocal A, López Martín JA, et al. Advances in cutaneous melanoma. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 2012; 14: 325–32.Google Scholar
  33. 33.
    Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29: 241–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493–501.PubMedCrossRefGoogle Scholar
  35. 35.
    Pirard D, Heenen M, Melot C, Vereecken P. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatol Basel Switz 2004; 208: 43–8.CrossRefGoogle Scholar
  36. 36.
    Hauschild A, Weichenthal M, Rass K, et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of > = 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 2010; 28: 841–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117–26.PubMedCrossRefGoogle Scholar
  38. 38.
    Eggermont AMM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366: 1189–96.PubMedCrossRefGoogle Scholar
  39. 39.
    Eggermont AMM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer Oxf Engl 1990 2012; 48: 218–25.Google Scholar
  40. 40.
    Monsour PD, Sause WT, Avent JM, Noyes RD. Local control following therapeutic nodal dissection for melanoma. J Surg Oncol 1993; 54: 18–22.PubMedCrossRefGoogle Scholar
  41. 41.
    O’Brien CJ, Petersen-Schaefer K, Ruark D, Coates AS, Menzie SJ, Harrison RI. Radical, modified, and selective neck dissection for cutaneous malignant melanoma. Head Neck 1995; 17: 232–41.PubMedCrossRefGoogle Scholar
  42. 42.
    Lee RJ, Gibbs JF, Proulx GM, Kollmorgen DR, Jia C, Kraybill WG. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000; 46: 467–74.PubMedCrossRefGoogle Scholar
  43. 43.
    Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994; 30: 795–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995; 2: 445–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Corry J, Smith JG, Bishop M, Ainslie J. Nodal radiation therapy for metastatic melanoma. Int J Radiat Oncol Biol Phys 1999; 44: 1065–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Stevens G, Thompson JF, Firth I, O’Brien CJ, Mc Carthy WH, Quinn MJ. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000; 88: 88–94.PubMedCrossRefGoogle Scholar
  47. 47.
    Ballo MT, Strom EA, Zagars GK, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002; 52: 964–72.PubMedCrossRefGoogle Scholar
  48. 48.
    Bonnen MD, Ballo MT, Myers JN, et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 2004; 100: 383–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Ballo MT, Bonnen MD, Garden AS, et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 2003; 97: 1789–96.PubMedCrossRefGoogle Scholar
  50. 50.
    Ballo MT, Zagars GK, Gershenwald JE, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 2004; 11: 1079–84.Google Scholar
  51. 51.
    Ballo MT, Garden AS, Myers JN, et al. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck 2005; 27: 718–21.PubMedCrossRefGoogle Scholar
  52. 52.
    Ballo MT, Ross MI, Cormier JN, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 2006; 64: 106–13.PubMedCrossRefGoogle Scholar
  53. 53.
    Burmeister BH, Smithers BM, Poulsen M, et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995; 19: 369–71.PubMedCrossRefGoogle Scholar
  54. 54.
    Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006; 66: 1051–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Conill C, Valduvieco I, Domingo-Domènech J, Arguis P, Vidal-Sicart S, Vilalta A. Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 2009; 11: 688–93.Google Scholar
  56. 56.
    Gyorki DE, Ainslie J, Joon ML, Henderson MA, Millward M, McArthur GA. Concurrent adjuvant radiotherapy and interferonalpha2b for resected high risk stage III melanoma–a retrospective single centre study. Melanoma Res 2004; 14: 223–30.PubMedCrossRefGoogle Scholar
  57. 57.
    Nguyen NP, Levinson B, Dutta S, et al. Concurrent interferonalpha and radiation for head and neck melanoma. Melanoma Res 2003; 13: 67–71.PubMedCrossRefGoogle Scholar
  58. 58.
    Hazard LJ, Sause WT, Noyes RD. Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity. Int J Radiat Oncol Biol Phys 2002; 52: 796–800.PubMedCrossRefGoogle Scholar
  59. 59.
    Conill C, Jorcano S, Domingo-Domènech J, et al. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res 2007; 17: 304–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007; 156: 337–45.PubMedCrossRefGoogle Scholar
  61. 61.
    Vereecken P, Mathieu A, Laporte M, et al. Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod. Dermatol Basel Switz 2003; 206: 279. 80.CrossRefGoogle Scholar
  62. 62.
    Bong AB, Bonnekoh B, Franke I, Schön MP, Ulrich J, Gollnick H. Imiquimod a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatol Basel Switz 2002; 205: 135–8.CrossRefGoogle Scholar
  63. 63.
    Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 2010; 116: 4139–46.PubMedCrossRefGoogle Scholar
  64. 64.
    Campana LG, Valpione S, Mocellin S, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 2012; 99: 821–30.PubMedCrossRefGoogle Scholar
  65. 65.
    Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and metaanalysis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2013; 39: 4–16.Google Scholar
  66. 66.
    Sivendran S, Pan M, Kaufman HL, Saenger Y. Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin Biol Ther 2010; 10: 1145–53.PubMedCrossRefGoogle Scholar
  67. 67.
    Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6: 941–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Holterhues C, van de Poll-Franse LV, de Vries E, Neumann HAM, Nijsten TEC. Melanoma patients receive more follow-up care than current guideline recommendations: a study of 546 patients from the general Dutch population. J Eur Acad Dermatol Venereol 2012; 26: 1389–95.PubMedCrossRefGoogle Scholar
  69. 69.
    Kruijff S, Bastiaannet E, Suurmeijer AJH, Hoekstra HJ. Detection of melanoma nodal metastases; differences in detection between elderly and younger patients do not affect survival. Ann Surg Oncol 2010; 17: 3008–14.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Mohr P, Eggermont AMM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol 2009; 20(Suppl 6): vi14–21.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Nashan D, Kocer B, Schiller M, Luger T, Grabbe S. Significant risk of a second melanoma in patients with a history of melanoma but no further predisposing factors. Dermatol Basel Switz 2003; 206: 76–7.CrossRefGoogle Scholar
  72. 72.
    Leiter U, Eigentler TK, Forschner A, et al. Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies. Clin Dermatol 2010; 28: 311–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Bafounta ML, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 2001; 137: 1343–50.PubMedCrossRefGoogle Scholar
  74. 74.
    Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008; 159: 669–76.PubMedGoogle Scholar
  75. 75.
    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199–206.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–16.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323–32.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Uren RF, Howman-Giles R, Chung D, Thompson JF. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma. J Surg Oncol 2011; 104: 405–19.PubMedCrossRefGoogle Scholar
  80. 80.
    Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135–47.PubMedCrossRefGoogle Scholar
  81. 81.
    Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 2011; 117: 4740–4706.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol 2006; 7: 919–24.PubMedCrossRefGoogle Scholar
  83. 83.
    Fletcher WS, Pommier RF, Lum S, Wilmarth TJ. Surgical treatment of metastatic melanoma. Am J Surg 1998; 175: 413–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery 1994; 115: 295–302.PubMedGoogle Scholar
  85. 85.
    Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapy for distant metastases of malignant melanoma. Cancer 2000; 89: 1983. 91.PubMedCrossRefGoogle Scholar
  86. 86.
    Ollila DW, Essner R, Wanek LA, Morton DL. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg Chic Ill 1960 1996; 131:975–979; 979-980.Google Scholar
  87. 87.
    Ollila DW, Hsueh EC, Stern SL, Morton DL. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 1999; 71: 209–13.PubMedCrossRefGoogle Scholar
  88. 88.
    Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 2004; 16: 155–60.PubMedCrossRefGoogle Scholar
  89. 89.
    Wood TF, DiFronzo LA, Rose DM, et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol 2001; 8: 658–62.PubMedCrossRefGoogle Scholar
  90. 90.
    Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progressionfree and overall survival benchmarks for future phase II trials. J Clin Oncol Off J Am Soc Clin Oncol 2008; 26: 527–34.CrossRefGoogle Scholar
  91. 91.
    Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 2012; 19: 2547–55.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494–500.PubMedCrossRefGoogle Scholar
  93. 93.
    Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867–76.PubMedCrossRefGoogle Scholar
  94. 94.
    Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877–88.PubMedCrossRefGoogle Scholar
  95. 95.
    Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol Off J Eur Soc Med Oncol ESMO 2013; 24: 2174–80.CrossRefGoogle Scholar
  97. 97.
    Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res Off J Am Assoc Cancer Res 2009; 15: 7412–20.CrossRefGoogle Scholar
  98. 98.
    Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707–14.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012; 6: 391–405.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012; 10: 107.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014; 120: 1695–701.PubMedCrossRefGoogle Scholar
  102. 102.
    Zimmer L, Vaubel J, Livingstone E, Schadendorf D. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 2012; 10: 475–86.Google Scholar
  103. 103.
    Ficha Técnica vemurafenib. medicamentosUsoHumano/informesPublicos/docs/IPT-zelboraf-melanoma. pdfGoogle Scholar
  104. 104.
    Al-Shaer M, Gollapudi D, Papageorgio C. Melanoma biomarkers: Vox clamantis in deserto (Review). Oncol Lett 2010; 1: 399–405.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Bronstein Y, Ng CS, Rohren E, et al. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol 2012; 198: 902–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Strobel K, Dummer R, Husarik DB, Pérez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007; 244: 566–74.PubMedCrossRefGoogle Scholar
  107. 107.
    Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002; 9: 646–53.PubMedCrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2015

Authors and Affiliations

  • Alfonso Berrocal
    • 1
  • Enrique Espinosa
    • 2
  • Severiano Marín
    • 3
  • Josep Malvehy
    • 4
  • David Moreno
    • 5
  • Maria Dolores Lozano
    • 6
  • Salvador Martin-Algarra
    • 7
  • Jose Antonio Lopez
    • 8
  • Carlos Conill
    • 9
  • Jose Luis Rodriguez-Peralto
    • 10
  1. 1.Department of OncologyHospital La PazMadridSpain
  2. 2.Service of OncologyHospital La PazMadridSpain
  3. 3.Plastic SurgeryConsorcio Hospital General UniversitarioValenciaSpain
  4. 4.Dermatology Department, Melanoma UnitHospital ClinicBarcelonaSpain
  5. 5.Dermatology UnitHospital Universitario Virgen MacarenaSevilleSpain
  6. 6.Department of PathologyClinica Universitaria de NavarraPamplonaSpain
  7. 7.Department of OncologyClinica Universitaria de NavarraPamplonaSpain
  8. 8.Department of OncologyUniversity of BarcelonaBarcelonaSpain
  9. 9.Department of Radiation Oncology, Hospital Clinic, Institut d’Investigacions Biomédiques August Pi i Sunyer (IDIBAPS)University of BarcelonaBarcelonaSpain
  10. 10.Department of PathologyHospital 12 de OctubreMadridSpain

Personalised recommendations